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the country was still relatively 
poor (with a gross domestic prod-
uct [GDP] half the size of Brit-
ain’s), Japan reached full health 
insurance coverage of its popula-
tion. In the next half-century, it 
continued to develop 
its health system and 
improve equity, even 
applying this principle 
of universal health coverage in 
its global health diplomacy.1 
Now, however, Japan faces serious 
fiscal pressure due to a sluggish 
economy and the rapid aging and 
low birth rate of its population 
— but it is striving to sustain its 
health system in the face of these 
challenges.
Japan followed a nonlinear path 
to universal coverage. Previous 
Japanese policymakers were some-
times motivated to develop the 
health system for reasons of polit-
ical economy that were unrelated 
to health. For example, Japan’s 
first national policy for health in-
surance was introduced in 1923, 
motivated in part by imperial vi-
sions and the desire for a strong 
and healthy workforce for war. 
During World War II, Japan 
achieved nearly 70% health insur-
ance coverage. Then, in the post-
war period, political competition 
among the major parties promot-
ed government efforts to expand 
coverage, as the conservative Lib-
eral Democratic Party sought to 
provide benefits to its rural con-
stituents and to weaken the agen-
das of the Socialist and Commu-
nist parties by redistributing social 
resources to industrial workers. 
Japan was not unique in this re-
gard: in countries such as Britain 
and Germany, the process of at-
taining universal health coverage 
also stretched over long periods 
and was advanced by various po-
litical motivations.2 Though such 
mixed origins don’t diminish the 
value of Japan’s health policy ac-
complishments, they do highlight 
the importance of viewing the 
process from historical and politi-
cal perspectives.
Japan’s achievements in health 
status are well known (see table). 
Since 1986, Japan has ranked first 
in the world in women’s life ex-
pectancy at birth, which reached 
87 years in 2014. Life expectancy 
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Four years ago, Japan celebrated 50 years of achieve-ment of good health at low cost and increasing 
equity for its population.1 In 1961, at the beginning 
of a period of rapid economic development, while 
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for Japanese men surpassed 80 
years in 2013. Japan’s infant mor-
tality rate, reported as 2.1 per 1000 
live births in 2013, is the lowest 
in the world. But a continuing de-
cline in birth rate means that the 
country’s population is shrink-
ing, even as it ages more rapidly 
than in other societies. The pro-
portion of people older than 65 
years increased from around 12% 
in 1990 to 25% in 2013, and the 
proportion of older people has 
exceeded the proportion of young 
people (0 to 14 years of age) since 
1997. This demographic transi-
tion has created huge fiscal and 
health care challenges.
In addition to improving health 
outcomes, Japan’s social insurance 
system has made incremental 
improvements in equity through 
cross-subsidies and tax transfers, 
which contributed to income re-
distribution in addition to risk 
pooling. As many countries have 
done, Japan expanded health cov-
erage population group by popu-
lation group, through policies de-
signed for different groups with 
differing levels of coverage (both 
in terms of benefits and funding) 
— thereby creating disparities 
and problems of fairness. Govern-
ment action and new social policy 
were required in order to reduce 
these inequities. Japan’s single 
reimbursement fee schedule (for 
all physicians and patients) and 
single benefit package for all so-
cial insurance programs created 
a foundation for equity in access. 
The government then increased 
equity by changing the copayment 
policies for the various insurance 
programs, reducing benefits for 
employees of private companies 
(by increasing their copayment 
rates), and increasing benefits for 
the elderly and non–employment-
based insurance plans (by reduc-
ing their copayment rates). Policy-
makers thus made the overall 
health system more equitable over 
time, reflecting the value that 
Japanese society places on egali-
tarianism.
Those achievements in equity 
are now at risk. Japan still has 
about 3500 insurance plans, with 
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Selected Characteristics of the Health Care System and Health Outcomes in Japan.*
Variable Value
Health expenditures in 2013
Per capita (U.S. $) 3,966
Percentage of GDP 10.3
Out-of-pocket (% of private health expenditures) 80.2
Public sources (% of total) 82.1
Health insurance
Percent of population covered >99.9
Funding sources Taxes and 
 premiums
Access
Hospital beds per 10,000 population in 2013 (no.) 133
Physicians per 1000 population in 2012 (no.) 2.3
Percent of total government health expenditures spent on mental  
health care in 2011
4.9
Clinics using electronic medical records in 2011 (%) 20.9
Physicians’ average monthly income in 2013 (U.S. $) 11,769
Life and death
Life expectancy at birth in 2013 (yr) 83.5
Additional life expectancy at 60 yr in 2013 (yr) 25.9
Deaths per 1000 population in 2013 (no.) 10.1
Infant deaths per 1000 live births in 2013 (no.) 2.1
Deaths of children <5 yr of age per 1000 live births in 2013 (no.) 3.0
Maternal deaths per 100,000 live births in 2013 (no.) 3.4
Fertility and childbirth
Average births per woman in 2014 (no.) 1.4
Births attended by skilled health staff in 2013 (%) 99.8
Preventive care
Colorectal-cancer screening generally available at primary care level Yes
Children 12–23 mo of age receiving measles immunization in 2013 (%) 95.5
Prevalence of chronic diseases (%)
Diabetes in persons 20–79 yr of age in 2014 5.1
HIV infection <0.1
Prevalence of risk factors (%)
Obesity in adults ≥20 yr of age in 2013 3.7
Smoking in adults ≥20 yr of age in 2013 19.3
* Data are from the Organization for Economic Cooperation and Development; the World Bank, 
Hashimoto et al.3; the Japan Ministry of Health, Labor, and Welfare; the World Health Organi-
zation; and the National Institute of Population and Social Security Research. GDP denotes 
gross domestic product, and HIV human immunodeficiency virus.
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varying premium levels, so some 
private companies or municipali-
ties provide better financial bene-
fits than others. The fragmented 
insurance plans are differentially 
affected by the increasing num-
ber of elderly people in Japan. 
As people age and retire, they move 
from employment-based plans 
to non–employment-based plans, 
whose costs per person increase 
as older enrollees are added. As 
a result, non–employment-based 
plans increasingly have financial 
problems, especially as compared 
with Japan’s employment-based 
plans. In an effort to reduce the 
financial problems for these plans 
and address the needs of the ag-
ing population, Japan introduced 
a national policy for long-term 
care insurance in 2000, and in 
2008, it created a new health in-
surance program for people over 
75 years of age.
Rising health care costs are a 
serious concern in Japan today: 
if the country takes no action, 
health expenditures could increase 
from the current 8% of GDP to 
around 11% by 2025.4 Rising 
costs are a result of structural 
problems in the health system, 
especially the rapidly aging pop-
ulation and the frequent use of 
high-cost technologies such as 
magnetic resonance imaging and 
relatively high-priced generic med-
icines (which cost 60% of brand-
name prices in Japan). Two de-
cades of economic stagnation 
during the 1990s and 2000s (the 
“lost decades”) also mean that 
health care costs have been tak-
ing a proportionately greater bite 
out of the GDP.
A final major challenge involves 
improving the quality of care in 
the Japanese system. Quality and 
efficiency have often been ig-
nored by Japan’s health policies. 
Existing government programs 
tend to focus on quantifying in-
puts and structures rather than 
on creating incentives to improve 
quality or addressing problems 
in outcomes. Some studies have 
suggested that postsurgical mor-
tality rates in large hospitals in 
Japan are as low as those report-
ed in other countries but that the 
quality of primary care and inpa-
tient chronic care services may be 
problematic.3 Japanese hospitals 
and clinics are poorly differentiat-
ed by level of services, and there 
is no standardized benchmarking 
to assess hospital performance.
The Japanese government is 
acutely aware of these challenges 
and the intersecting crises of rapid 
aging and fiscal sustainability, 
which are further confounded by 
the health system’s complex gov-
ernance, including the mecha-
nism for defining the fee sched-
ule, as well as people’s changing 
expectations about both medical 
and nonmedical aspects of health 
care.1 The government is trying 
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MYOCARDIAL INFARCTION
A 55-year-old man with no serious health conditions has a moderately 
severe myocardial infarction.
In his suburban Tokyo home, Tanaka-san wakes up one day with 
chest pain. When the pain continues for 30 minutes, his family be-
comes worried and calls an ambulance, which arrives in 5 minutes. 
The emergency medicine team contacts the dispatcher, who asks a 
neighborhood general hospital whether there is room for an admis-
sion but is told that the coronary care unit is full. After 30 minutes of 
calls, the dispatcher finally finds a private hospital (with 150 beds) 
20 minutes away that is willing to accept the patient.
This hospital has heart catheterization, MRI, and other equip-
ment, and the emergency doctor in charge obtains an electrocardio-
gram and serum enzyme test to diagnose a myocardial infarction. 
A cardiologist is called to perform a cardiac catheterization, which 
reveals an infarction of a high lateral branch of the left anterior 
descending artery. A stent is immediately inserted, and reper-
fusion is established. The patient then stays in the hospital for 
2 weeks.
The total hospitalization fee reaches ¥1.5 million (U.S. $12,000, 
including two heart stents for $6,700 and facility fees of $2,500). 
Coverage from Japan’s High-Cost Medical Care Benefit System 
 allows Tanaka-san to pay only $1,300, to cover the fee for a single-
bed room for a few nights, insurance copayments, and some extra 
meal fees.
The day before discharge, Tanaka-san receives instructions on 
medication and lifestyle counseling. He is instructed to visit the out-
patient clinic 2 weeks later. Because the hospital is far from his home, 
the patient asks for an introduction to a nearby general practitioner. 
Eight months later, however, follow-up angiography to see whether 
any restenosis has occurred has still not been done.
Hideki Hashimoto, Masayo Matsuzaki, and Mikko Kanda contributed to this case 
study.
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to find ways to ensure fiscal sus-
tainability, in response to the com-
mitment made by Prime Minister 
Shinzō Abe to eliminate deficits 
by 2020. Recent laws seek to pro-
mote both the differentiation of 
hospitals by function and the 
community-level integration of 
medical treatment, long-term care, 
and preventive care by 2025. Japan 
is also considering a proposal to 
consolidate insurance plans at the 
prefectural level. In 2014, the Abe 
cabinet endorsed a government 
health care strategy that aims to 
facilitate the development of in-
novative technologies through a 
new Agency for Medical Research 
and Development. But these 
changes are not likely to be suf-
ficient to address the profound 
fiscal and demographic problems 
facing the country. Maintaining 
Japan’s current system by increas-
ing premiums or taxes while cut-
ting benefits, as was done in the 
past, might buy some time — 
but it would be very costly po-
litically and would not resolve 
fundamental structural problems. 
Incremental changes at the mar-
gins will no longer suffice.
Instead, we believe that Japan 
needs a new vision of health care 
and health systems for the future. 
In June 2015, an advisory panel 
of young experts, appointed by 
Health Minister Yasuhisa Shiozaki, 
presented its vision of health care 
for Japan in 2035.5 The panel’s 
report proposes a paradigm shift 
for Japan’s health system, to re-
direct its focus from inputs to 
outcomes, from the quantity of 
services provided to patients’ con-
cerns about quality, from govern-
mental regulation to professional 
self-regulation, from cure to care 
and well-being, and from special-
ization of services to integrated 
approaches across medical and so-
cial service sectors. The new health 
system would continue to empha-
size fairness and solidarity, while 
building on individual patient val-
ues and desires and emphasizing 
global health perspectives.5 The 
government, recognizing that 
Japan needs new solutions for its 
profound problems, has explicitly 
called on the younger generation 
to produce innovative ideas for 
improving the health system.
The hope is that Japan will be 
able to mobilize new ideas, sys-
tems, and technologies to assist 
its growing elderly population and 
conform to changing social val-
ues and growing structural con-
straints and that the Japanese 
government will be able to jump-
start the economy and get it grow-
ing again (using Prime Minister 
Shinzō Abe’s strategies of govern-
ment spending, monetary easing, 
and structural reforms, known as 
“Abenomics”), even as the popu-
lation continues to age and 
shrink. More and more countries 
are confronting similar challeng-
es, but Japan is first in line. Ac-
complishing these multiple and 
sometimes conflicting goals will 
not be easy, but that’s the chal-
lenge that Japan’s health system 
and society must tackle.
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PREGNANCY AND CHILDBIRTH
A healthy 23-year-old woman is pregnant for the first time.
Suzuki-san is married and lives in a Tokyo suburb. Realizing that 
she is pregnant, she goes to a neighborhood hospital to consult an 
obstetrician, who confirms the pregnancy, and she pays him ¥8,000 
(U.S. $64), since pregnancy is not covered by Japan’s national health 
insurance.
Suzuki-san next visits the nearby municipal health center. She 
notifies the authorities about her pregnancy and receives the Mother 
and Child Health Handbook, to record information from the physi-
cian’s medical examination, any concerns about the pregnancy, ob-
servations about the newborn baby, and ongoing observations 
about the infant. She also receives a pregnancy health checkup con-
sultation ticket and an ultrasound inspection visit ticket, which pro-
vide her with partial financial support for these antenatal services.
During her pregnancy, Suzuki-san follows the typical schedule of 
14 visits for health checkups at her hospital. At each visit, she is ex-
amined by the obstetrician for risks and symptoms of pregnancy 
complications and meets with the midwife for nutritional and men-
tal health care and support.
At 20 weeks, she decides on a hospital and on a vaginal delivery. 
After the birth, Suzuki-san stays as an inpatient for 5 days. She pays 
a total of ¥620,000 ($5,000) for all hospital services and is reim-
bursed by health insurance for ¥420,000 ($3,400).
Two weeks after the birth, a midwife will visit Suzuki-san at home 
at no charge. Two weeks later, Suzuki-san will bring her infant to the 
hospital where she gave birth, where she will see an obstetrician-
gynecologist and her child will see a pediatrician.
Hideki Hashimoto, Masayo Matsuzaki, and Mikko Kanda contributed to this case study.
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New Math on Drug Cost-Effectiveness
Peter B. Bach, M.D., M.A.P.P.
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Nowadays, the reality of ex-orbitant drug pricing over-
shadows even the most excep-
tional stories of drug efficacy. 
It’s true that we’re making huge 
biomedical strides, yet it’s also 
true that prices for new drugs 
are rising, as are prices of exist-
ing treatments.
A case in point is nivolumab, 
which, as Motzer et al. report in 
this issue of the Journal (pages 
1803–1813), appears to extend 
median survival in patients with 
metastatic renal-cell cancer by 
nearly half a year. But the cost to 
insurers and patients of using 
the drug for this condition — by 
my estimate, around $65,000 for 
Medicare beneficiaries and up to 
twice that for commercially in-
sured patients — can’t be ignored.
The price hurts patients, limit-
ing their access and depleting 
their savings. Under the current 
system of insurance, many pa-
tients have to pay large sums out 
of pocket, and research shows 
that when that happens, some 
patients will stop taking medica-
tions even if they are very effec-
tive.1 The high costs of cancer care 
also drive patients into bankruptcy.
The problem is particularly 
acute for Medicare beneficiaries, 
who account for the majority of 
patients with cancer in the United 
States. For nivolumab, a drug 
categorized as physician-admin-
istered and thus insured under 
Medicare’s Part B benefit, Medi-
care assigns 20% of the cost to 
the patient. Although most Med-
icare beneficiaries have extra in-
surance to cover this expense 
— through Medicaid, an employer-
based plan, or a private-market 
product such as Medigap — ap-
proximately 15% do not, accord-
ing to the 2011 Medicare Current 
Beneficiary Survey. In other words, 
a sizable number of Medicare pa-
tients receiving this treatment 
could owe about $13,000 — 
more than half the typical annual 
median income among Medicare 
beneficiaries, which is $24,150 
(Medicare beneficiaries who lack 
additional coverage actually tend 
to have incomes below this level).
Exacerbating this problem, 
Medicare sets no upper limit on 
coinsurance under Part B (or un-
der Part D) even though commer-
cial plans regulated under the 
Affordable Care Act do have out-
of-pocket maximums. Federal law 
prevents the maker of nivolumab 
(Bristol-Myers Squibb) from pro-
viding assistance to patients who 
cannot afford the treatment. Pro-
grams such as Genentech’s for 
Avastin, in which beneficiaries 
receive the drug free once they 
have spent a certain amount in a 
calendar year, are rare.2
Policymakers, stymied by the 
rising cost of drugs, might think 
that an approach that relies on 
cost-effectiveness analyses would 
help the health care system deal 
with the high price of new treat-
ments. After all, the United King-
dom sets standards for cost-effec-
tiveness at about $40,000 per 
quality-adjusted life-year for new 
drugs, and overall health care 
spending there is a fraction of 
what it is in the United States.
Of course, this potential solu-
tion remains theoretical today, 
since Medicare cannot limit drug 
access on the basis of cost-effec-
tiveness; rather, laws require 
Medicare to cover all cancer drugs 
for all uses approved by the Food 
and Drug Administration (FDA) or 
listed in recognized compendia 
and to pay the price the manu-
facturer chooses to charge. But 
even if Medicare could set such 
limits, I believe that policymakers 
would find limited relief from 
the approach.
Expensive drugs can still seem 
deceptively cost-effective, because 
of the long upward spiral we have 
seen in the prices of cancer treat-
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